Here, we have shown that CD8 TIL immune exclusion in TNC‐rich stroma correlates with worsened prognosis and identified novel parameters for stratification of breast cancer patients, irrespective of subtype, likely to benefit from ICT. This evidence concerns the gene CD8A and breast cancer.